Methods of Analyzing Virus-Derived Therapeutics

Researchers at the National Cancer Institute ’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.IC: NCINIH Ref. No.: E-240-2015Advantages: Provides a cost- and time-effective means of assaying a virus-derived therapeutic, such as oncolytic viruses, for viral sequence variants, for regulatory approval;RNA virus preparation steps increase the amount of viral RNA obtained;Demonstrated superiority of massively parallel sequencing ( “MPS”) over mutant analysis by PCR and restriction enzyme cleavage (“MAPREC”) analysis.Applications: Improved methods for detecting mutations in GMP-manufactured virus-derived therapeutics, including viruses, viral template plasmids, or vaccines;The method allows for at least two different virus-derived therapeutics to be assayed simultaneously.Development Status: ClinicalUpdated On: Dec 19, 2017Provider Classifications: Patent Application: 62/199,663PCT/US2016/044788Publications: Licensing Contacts: Lead Inventor: Inventor IC: NCIAmerican International Biotechnology, LLCAmerican International Biotechnology, LLCAmerican International Biotechnology, LLCInventor Lab URL: https://ncifrederick.cancer.gov/Programs/Science/BDP/Default.aspxInv Is lead: LPM Phone: [phone]LPM E...

Source: NIH OTT Licensing Opportunities - December 20, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research